RxNorm 2472329
rituximab-arrx 10 MG/ML [Riabni]
RxNorm Semantic Concepts
RxNorm semantic concepts for the RxCUI 2472329 unique identifier include: rituximab-arrx 10 MG/ML [Riabni] (12529453) and riTUXimab-arrx 10 MG/ML [Riabni] (12530067).
RxNorm Atom ID: 12529453 - Semantic Branded Drug Component
rituximab-arrx 10 MG/ML [Riabni]
- RXCUI:
- 2472329 - RxNorm Unique Identifier for a concept (Concept ID)
- LAT:
- ENG - Language of the Term
- RXAUI:
- 12529453 - Unique identifier for the atom (RxNorm Atom ID)
- Is Prescribable?
- YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
- Concept Description:
- rituximab-arrx 10 MG/ML [Riabni] - Description of concept identifier
- Term Type (TTY):
- SBDC - Term type in source with name and description
- Term Type Name:
- Semantic Branded Drug Component - Name of term type in source
- Term Type Description:
- Ingredient + Strength + Brand Name - Description of term type in source
- Code:
- 2472329 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
- Suppress Flag:
- N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility. - CVF:
- 4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
- Source:
- RXNORM - Concept source abbreviation
- Source Name:
- RxNorm Vocabulary - The official name for a source
- Source Version:
- 20AA_240401F - The source version
- Source Date:
- March 04, 2024 - RxNorm data last updated
- Source License Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information - Source Content Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information - Source Short Name:
- RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server
RxNorm Atom ID: 12530067 - Tall Man Lettering Synonym
riTUXimab-arrx 10 MG/ML [Riabni]
- RXCUI:
- 2472329 - RxNorm Unique Identifier for a concept (Concept ID)
- LAT:
- ENG - Language of the Term
- RXAUI:
- 12530067 - Unique identifier for the atom (RxNorm Atom ID)
- Is Prescribable?
- YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
- Concept Description:
- riTUXimab-arrx 10 MG/ML [Riabni] - Description of concept identifier
- Term Type (TTY):
- TMSY - Term type in source with name and description
- Term Type Name:
- Tall Man Lettering Synonym - Name of term type in source
- Term Type Description:
- Tall Man Lettering synonym of another TTY, given to distinguish between commonly confused drugs. - Description of term type in source
- Code:
- 2472329 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
- Suppress Flag:
- N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility. - CVF:
- 4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
- Source:
- RXNORM - Concept source abbreviation
- Source Name:
- RxNorm Vocabulary - The official name for a source
- Source Version:
- 20AA_240401F - The source version
- Source Date:
- March 04, 2024 - RxNorm data last updated
- Source License Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information - Source Content Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information - Source Short Name:
- RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server
* This product uses publicly available data courtesy of the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Patient Education
Rituximab Injection
Rituximab injection products are used alone or with other medications to treat various types of non-Hodgkin's lymphoma (NHL; a type of cancer that begins in a type of white blood cells that normally fights infection). Rituximab injection products are also used with other medications to treat chronic lymphocytic leukemia (CLL; a type of cancer of the white blood cells). Rituximab injection (Rituxan) is also used with methotrexate (Otrexup, Rasuvo, Xatmep, others) to treat the symptoms of rheumatoid arthritis (RA; a condition in which the body attacks its own joints, causing pain, swelling, and loss of function) in adults who have already been treated with a certain type of medication called a tumor necrosis factor (TNF) inhibitor. Rituximab injection (Rituxan, Ruxience) is also used in adults and children 2 years of age and older along with other medications to treat granulomatosis with polyangiitis (Wegener's Granulomatosis) and microscopic polyangiitis, which are conditions in which the body attacks its own veins and other blood vessels, which causes damage to organs, such as the heart and lungs. Rituximab injection (Rituxan) is used to treat pemphigus vulgaris (a condition that causes painful blisters on the skin and the lining the mouth, nose, throat and genitals). Rituximab injection products are in a class of medications called monoclonal antibodies. They treat the various types of NHL and CLL by killing cancer cells. Certain rituximab injection products also treat rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris by blocking the activity of the part of the immune system that may damage the joints, veins, and other blood vessels.
[Learn More]
* Please review the disclaimer below.